Researchers have uncovered three new genes that are linked to the possibility of developing Alzheimer’s disease; potentially unlocking new treatment possibilities for patients.
Novartis and Amgen have announced that Aimovig™ has been approved by the US FDA for the preventive treatment of migraine in adults.
A recent trial has determined that moderate-to-high intensity exercise does not slow cognitive decline in individuals with dementia.
The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.
This week, our industry report covers neuroblastoma, DUB inhibitors for neurodegenerative diseases and pediatric multiple sclerosis.
An international team has utilized neuronal cells programmed from genetically identical pigs to eliminate the need for immunosuppression measures.
Scientists reveal that a molecule normally used by the immune system to prevent excessive damage may actually contribute to chronic white matter injury.
Low levels of vasopressin may be linked to low social ability in monkeys and autism in children, indicating that the hormone could be a biomarker for autism.
In partnership with The Brain Tumour Charity, the Cancer Research UK Brain Tumour Awards hope to tackle six major themes in brain tumor research.
This week, the American Academy of Neurology (CA, USA) presented findings from two studies that investigate the impact of ocrelizumab in multiple sclerosis patients.